Rapid health technology assessment of toripalimab combined with chemotherapy in the treatment of locally advanced or metastatic non-small cell lung cancer
- VernacularTitle:特瑞普利单抗联合化疗用于局部晚期或转移性NSCLC的快速卫生技术评估
- Author:
Yuping YANG
1
;
Yuan ZHOU
1
;
Qirui TAI
1
;
Mili SHI
1
;
Yijie SHI
1
;
Jieya WANG
1
;
Huan HU
1
;
Yuan ZHANG
1
;
Yi LIU
2
;
Yue WANG
3
Author Information
1. Dept. of Pharmacy，People’s Hospital of Yuxi City，Yunnan Yuxi 653100，China
2. Dept. of Pharmacy，Peking University People’s Hospital，Beijing 100044，China
3. Oncology Center，People’s Hospital of Yuxi City，Yunnan Yuxi 653100，China
- Publication Type:Journal Article
- Keywords:
toripalimab;
chemotherapy;
non-small cell lung cancer;
advanced stage;
metastasis;
rapid health technology
- From:
China Pharmacy
2025;36(20):2593-2598
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy， safety and cost-effectiveness of toripalimab （Tor） combined with chemotherapy （CT） in the treatment of locally advanced or metastatic non-small cell lung cancer （NSCLC）. METHODS PubMed， the Cochrane Library， Embase， Web of Science， CBM， CNKI， Wanfang Data， and Health Technology Assessment （HTA） related websites were searched to collect the HTA reports， systematic reviews/meta-analyses and pharmacoeconomic studies of Tor+CT in the treatment of locally advanced or metastatic NSCLC from database/website inception to March 31， 2025. After data extraction and quality evaluation， the results of the included studies were analyzed descriptively. RESULTS A total of eleven studies were included， involving five systematic reviews/meta-analyses， and six pharmacoeconomic studies. Among the five systematic reviews/ meta-analyses， two were of high quality， while there was one each of moderate， low， and very low quality. All six pharmacoeconomic studies were of good quality. In terms of efficacy， compared with CT， Tor+CT significantly improved patients’ progression-free survival （PFS） and overall survival （P＜0.05）. In addition， compared with ipilimumab+CT， durvalumab， durvalumab+tremelimumab and sugemalimab+CT， Tor+CT could also improve the PFS （P＜0.05）. In terms of safety， there was no significant difference in the incidence of grade≥3 adverse events between patients receiving Tor+CT and CT （P＞0.05）； while Tor+CT had a lower incidence of grade≥3 adverse E-mail： events， compared with camrelizumab+CT， pembrolizumab+ 3233255290@qq.com ipilimumab， nivolumab+CT and atezolizumab+CT （P＜0.05）.In terms of cost-effectiveness， Tor+CT treatment had certain cost-effectiveness advantages， compared with CT. CONCLUSIONS Compared with CT， other programmed death-1/programmed death-ligand 1 inhibitors alone， or their combination with CT， Tor+CT for the treatment of locally advanced or metastatic NSCLC has good efficacy， safety and cost-effectiveness.
